A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies
PLOS ONE · 22.06.2023 · 18 (6) · e0273884
DOI: 10.1371/journal.pone.0273884 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 22.06.2023. Verfasst von Alex Shepherd und 6 weiteren Autor:innen. Beteiligte Einrichtung: Human Health Therapeutics Research Centre, National Research Council, Ottawa, Canada. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Antibodies, Bispecific. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Canada Human Health Therapeutics Research Centre.
Abstract (Originalsprache)
Bi-specific T-cell engager antibodies (BiTEs) are synthetic fusion molecules that combine multiple antibody-binding domains to induce active contact between T-cells and antigen expressing cells in the body. Blinatumomab, a CD19-CD3 BiTE is now a widely used therapy for relapsed B-cell malignancies, and similar BiTE therapeutics have shown promise for treating various other forms of cancer. The current process for new BiTE development is time consuming and costly, requiring characterization of the individual antigen binding domains, followed by bi-specific design, protein production, purification, and eventually functional screening. Here, we sought to establish a more cost-efficient approach for generating novel BiTE sequences and assessing bioactivity through a function first approach without purification. We generate a plasmid with a bi-modular structure to allow high-throughput exchange of either binding arm, enabling rapid screening of novel tumour-targeting single chain variable (scFv) domains in combination with the well-characterized OKT3 scFv CD3-targeting domain. We also demonstrate two systems for high throughput functional screening of BiTE proteins based on Jurkat T cells (referred to as BiTE-J). Using BiTE-J we evaluate four EGFRvIII-scFv sequenced in BiTE format, identifying two constructs with superior activity for redirecting T-cells against the EGFRvIII-tumour specific antigen. We also confirm activity in primary T cells, where novel EGFRvIII-BiTEs induced T cell activation and antigen selective tumor killing. We finally demonstrate similar exchange the CD3-interacting element of our bi-modular plasmid. By testing several novel CD3-targeting scFv elements for activity in EGFRvIII-targeted BiTEs, we were able to identify highly active BiTE molecules with desirable functional activity for downstream development. In summary, BiTE-J presents a low cost, high-throughput method for the rapid assessment of novel BiTE molecules without the need for purification and quantification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Human Health Therapeutics Research Centre, National Research Council, Ottawa, Canada.
- Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada.
- Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, Canada.
ORCID-Profile: Scott McComb
Förderung
- National Research Council of Canada Human Health Therapeutics Research Centre
Zitieren
APA
Shepherd, A., Bennychen, B., Marcil, A., Bloemberg, D., Pon, R. A., Weeratna, R. D., & McComb, S. (2023). A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies. PLOS ONE, 18(6), e0273884. https://doi.org/10.1371/journal.pone.0273884
Vancouver
Shepherd A, Bennychen B, Marcil A, Bloemberg D, Pon RA, Weeratna RD, et al. A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies. PLOS ONE. 2023;18(6):e0273884. doi:10.1371/journal.pone.0273884
BibTeX
@article{Shepherd2023,
author = {Shepherd, Alex and Bennychen, Bigitha and Marcil, Anne and Bloemberg, Darin and Pon, Robert A and Weeratna, Risini D and McComb, Scott},
title = {A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {6},
pages = {e0273884},
doi = {10.1371/journal.pone.0273884}
}
EUVIMED